Abstract

Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia-reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone-related compound, exhibits antiplatelet and anti-inflammatory activities. Targeting inflammatory responses is a potential strategy for ameliorating hepatic injury during HS/R. Whether hinokitiol prevents hepatic injury during HS/R remains unclear. In the present study, we determined the role of hinokitiol following HS/R. The in vivo assays revealed that hinokitiol markedly attenuated HS/R-induced hepatic injury. Hinokitiol could inhibited NF-κB activation and IL-6 and TNF-α upregulation in liver tissues. Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2. These findings suggest that hinokitiol can ameliorate liver injury following HS/R, partly through suppression of inflammation and apoptosis. Furthermore, the in vitro data revealed that hinokitiol significantly reversed hypoxia/reoxygenation (H/R)-induced cell death and apoptosis in the primary hepatocytes. Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation. Moreover, hinokitiol attenuated H/R-stimulated NF-κB activation and reduced the levels of IL-6 and TNF-α mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury. Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF-κB activation.

Original languageEnglish
Pages (from-to)1723-1734
Number of pages12
JournalJournal of Cellular and Molecular Medicine
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Hemorrhagic Shock
Liver
Wounds and Injuries
Resuscitation
Therapeutics
Caspase 3
beta-thujaplicin
Hepatocytes
Interleukin-6
Down-Regulation
Tropolone
Apoptosis
Inflammation
Peroxisome Proliferator-Activated Receptors
Liver Failure
Reperfusion Injury
Cell Death
Anti-Inflammatory Agents
Up-Regulation

Keywords

  • Hemorrhagic shock
  • hinokitiol
  • liver
  • resuscitation
  • trauma

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Cite this

New therapeutic strategy of hinokitiol in haemorrhagic shock-induced liver injury. / Lu, Wan-Jung; Lin, Kuan-Hung; Tseng, Mei-Fang; Yuan, Kuo-Ching; Huang, Hung-Chang; Sheu, Joen-Rong; Chen, Ray-Jade.

In: Journal of Cellular and Molecular Medicine, Vol. 23, No. 3, 01.03.2019, p. 1723-1734.

Research output: Contribution to journalArticle

@article{4ea982122d3745a4bb0fc75bb11fad4a,
title = "New therapeutic strategy of hinokitiol in haemorrhagic shock-induced liver injury",
abstract = "Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia-reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone-related compound, exhibits antiplatelet and anti-inflammatory activities. Targeting inflammatory responses is a potential strategy for ameliorating hepatic injury during HS/R. Whether hinokitiol prevents hepatic injury during HS/R remains unclear. In the present study, we determined the role of hinokitiol following HS/R. The in vivo assays revealed that hinokitiol markedly attenuated HS/R-induced hepatic injury. Hinokitiol could inhibited NF-κB activation and IL-6 and TNF-α upregulation in liver tissues. Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2. These findings suggest that hinokitiol can ameliorate liver injury following HS/R, partly through suppression of inflammation and apoptosis. Furthermore, the in vitro data revealed that hinokitiol significantly reversed hypoxia/reoxygenation (H/R)-induced cell death and apoptosis in the primary hepatocytes. Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation. Moreover, hinokitiol attenuated H/R-stimulated NF-κB activation and reduced the levels of IL-6 and TNF-α mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury. Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF-κB activation.",
keywords = "Hemorrhagic shock, hinokitiol, liver, resuscitation, trauma",
author = "Wan-Jung Lu and Kuan-Hung Lin and Mei-Fang Tseng and Kuo-Ching Yuan and Hung-Chang Huang and Joen-Rong Sheu and Ray-Jade Chen",
note = "{\circledC} 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/jcmm.14070",
language = "English",
volume = "23",
pages = "1723--1734",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - New therapeutic strategy of hinokitiol in haemorrhagic shock-induced liver injury

AU - Lu, Wan-Jung

AU - Lin, Kuan-Hung

AU - Tseng, Mei-Fang

AU - Yuan, Kuo-Ching

AU - Huang, Hung-Chang

AU - Sheu, Joen-Rong

AU - Chen, Ray-Jade

N1 - © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia-reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone-related compound, exhibits antiplatelet and anti-inflammatory activities. Targeting inflammatory responses is a potential strategy for ameliorating hepatic injury during HS/R. Whether hinokitiol prevents hepatic injury during HS/R remains unclear. In the present study, we determined the role of hinokitiol following HS/R. The in vivo assays revealed that hinokitiol markedly attenuated HS/R-induced hepatic injury. Hinokitiol could inhibited NF-κB activation and IL-6 and TNF-α upregulation in liver tissues. Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2. These findings suggest that hinokitiol can ameliorate liver injury following HS/R, partly through suppression of inflammation and apoptosis. Furthermore, the in vitro data revealed that hinokitiol significantly reversed hypoxia/reoxygenation (H/R)-induced cell death and apoptosis in the primary hepatocytes. Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation. Moreover, hinokitiol attenuated H/R-stimulated NF-κB activation and reduced the levels of IL-6 and TNF-α mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury. Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF-κB activation.

AB - Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia-reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone-related compound, exhibits antiplatelet and anti-inflammatory activities. Targeting inflammatory responses is a potential strategy for ameliorating hepatic injury during HS/R. Whether hinokitiol prevents hepatic injury during HS/R remains unclear. In the present study, we determined the role of hinokitiol following HS/R. The in vivo assays revealed that hinokitiol markedly attenuated HS/R-induced hepatic injury. Hinokitiol could inhibited NF-κB activation and IL-6 and TNF-α upregulation in liver tissues. Moreover, hinokitiol reduced caspase-3 activation, upregulated Bax and downregulated Bcl-2. These findings suggest that hinokitiol can ameliorate liver injury following HS/R, partly through suppression of inflammation and apoptosis. Furthermore, the in vitro data revealed that hinokitiol significantly reversed hypoxia/reoxygenation (H/R)-induced cell death and apoptosis in the primary hepatocytes. Hinokitiol prevented H/R-induced caspase-3 activation, PPAR cleavage, Bax overexpression and Bcl-2 downregulation. Moreover, hinokitiol attenuated H/R-stimulated NF-κB activation and reduced the levels of IL-6 and TNF-α mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury. Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF-κB activation.

KW - Hemorrhagic shock

KW - hinokitiol

KW - liver

KW - resuscitation

KW - trauma

UR - http://www.scopus.com/inward/record.url?scp=85061660756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061660756&partnerID=8YFLogxK

U2 - 10.1111/jcmm.14070

DO - 10.1111/jcmm.14070

M3 - Article

VL - 23

SP - 1723

EP - 1734

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 3

ER -